Startup Bexorg, led by Zvonimir Vrselja, keeps human brains alive to test drugs. Their BrainEx system sustains brain cells for 24 hours to improve drug development and reduce animal testing.

Bexorg wins $28.3M ARPA-H award to keep human donor brains alive up to 2 weeks for drug testing. Co-founded by Yale's Nenad Sestan and CEO Zvonimir Vrselja.

The Harvard lab of David Sinclair discusses a chemical cocktail it named SL-100 which, delivered in pill form, restored youthful gene expression in brain organoids and extended healthy lifespan in nor...

Beam Therapeutics sued YolTech's Yuxuan Wu & Zi Jun Wang and Serapha Bio for allegedly stealing trade secrets related to CRISPR base editing & lipid nanoparticle tech.

Drugs like Trikafta, first approved in 2019, have changed cystic fibrosis from a death sentence to a manageable chronic condition for the vast majority of patients. But the drug is only approved for c...

Vivodyne, backed by about $80M, grows vascularized human tissues to screen drugs as the FDA and NIH push alternatives to animal testing.

Endpoints 11: SonoThera is using ultrasound and microbubbles to push full-length dystrophin into muscle, with a $125M Series B and a 2027 trial.

Endpoints 11: ARCH-backed Medici Therapeutics is pairing personalized mRNA cancer vaccines with TIL cell therapy, with $50M+ more coming in a Series A.

Endpoints Executive Editor Drew Armstrong on why picking the 2026 Endpoints 11 was the hardest yet, and what to expect at the Sept. 24 Boston gala.

Stanford's Sergiu Pasca bred mice lacking cortex/hippocampus for the first time, replacing cells with human neurons, aiding neuropsychiatric research including frontotemporal dementia and autism.

Two pediatric deaths in Chinese CRISPR trials reignite debate over AAV delivery risks, as many of the 15 genetic-medicine experts Endpoints spoke with point to high viral doses rather than gene editin...

Typewriter Therapeutics raises $56M Series A to build RNA-based jumping-gene therapies for in vivo CAR-T and genetic liver disease.

ARPA-H awards up to $125M across 5 teams, including Waterfall Scientific, to build automated systems that can make personalized RNA medicines in under a week.

FDA approves Revolution Medicines' daraxonrasib (Rasonque) for second-line pancreatic cancer, after it nearly doubled survival in a Phase 3 to 13.2 months vs. 6.7 months on chemo.

Aurora Therapeutics, the first bespoke CRISPR startup, lays off staff and drops its PKU program as CEO Ed Kaye exits, months after a $16M seed round.

GOP Reps. Moolenaar & Cline urge FDA's Diamantas to reject Chinese clinical trial data unless sites are audited annually, citing patient safety risks & 3 deaths.

RiboX confirms a patient died in its unregulated China trial for RXIM002, an in vivo CAR-T therapy — the third such disclosed death in recent weeks.

China’s cheap, fast and quiet system for testing cutting-edge medicines is facing scrutiny after the deaths of three people in investigator-initiated trials.

RiboX confirms a patient died in its unregulated China trial for RXIM002, an in vivo CAR-T therapy — the third such disclosed death in recent weeks.

GSK has launched a 33,600-person Finland trial of Shingrix to test if shingles vaccine reduces dementia risk in those 76+.

We interview Betty Tijms of Alzheimer Center Amsterdam, who has identified 5 Alzheimer's subtypes and urges drugmakers to treat the condition as multiple diseases for better trials.

We interview Betty Tijms of Alzheimer Center Amsterdam, who has identified 5 Alzheimer's subtypes and urges drugmakers to treat the condition as multiple diseases for better trials.

Nava Therapeutics discloses it has raised $89M as it targets in vivo CAR-T and kidney delivery with novel lipid nanoparticles.

Biogen's tau-lowering diranersen slows Alzheimer's decline 26% at the lowest dose in Phase 2, but an inverse dose response and a missed endpoint cloud the data.

ARPA-H taps 7 teams for up to $160M to build bespoke gene editing drugs, betting on Baby KJ's playbook — but some scientists say funding falls short.

Endpoints opens nominations for its 2026 Endpoints 11 awards; submit standout private biotech startups by July 14 ahead of the Sept. 24 gala dinner.

Spot Biosystems emerges from stealth with $40M raised, reporting early human data showing dystrophin restoration in two children with Duchenne muscular dystrophy.

UCSF spinout Kopra Bio has raised $9.1M to inject a genetically engineered virus into glioblastoma patients in a China trial.

Last month, Ascidian Therapeutics presented the first data suggesting a new way to fix broken genes may be safe in people. Now Eli Lilly has struck a deal with the startup.

The Allen Institute is launching a $200 million initiative to explore specific neurodegenerative diseases and even develop drugs for those conditions.

Tune Therapeutics' new method of CRISPR-based gene editing shows promise in curtailing chronic hepatitis B infections.

Yoltech Therapeutics, one of China’s most prolific gene editing companies has raised its biggest round of funding ahead of plans to go public in Hong Kong.

New York City-based startup Waypoint Bio has raised $20 million in series A financing to test multiple cell therapies in China.